Discounted pricing as part of a patient access scheme has reversed a three-year-old rejection of GlaxoSmithKline PLC's oral platelet booster, Revolade (eltrombopag) for reimbursement by the U.K.'s National Health Service.
The National Institute for Health and Care Excellence (NICE) issued draft final guidance June 12 saying Revolade, marketed as Promacta in the U.S., was an option for the treatment of...